Belantamab combination for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have multiple myeloma that has returned or not responded to at least 2 previous treatments (including a proteasome inhibitor like bortezomib and an immunomodulatory drug like lenalidomide).
- Your cancer shows measurable signs, like a certain level of M-protein in blood or urine, or free light chains in the blood.
- You have not had a stem cell transplant in the last 100 days, and if you have had one, you have no active infections.
- You are able to care for yourself (ECOG 0-2).
- Your liver and kidney function are within acceptable limits, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
This study tests a combination of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) for people with multiple myeloma who also have moderate liver problems. The goal is to see if this combination is safe and works well for them.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.